Showing 1 - 20 results of 34 for search 'Alex C. Spyropoulos', query time: 0.05s Refine Results
  1. 1
    New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients

    New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients by Kira MacDougall, Alex C Spyropoulos

    Published 2020-04-01
    Get full text
    Article
  2. 2
    Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors

    Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors by Alex C. Spyropoulos, Dimitrios Giannis, Mark Goldin

    Published 2021-07-01
    Get full text
    Article
  3. 3
    System-Wide Thromboprophylaxis Interventions for Hospitalized Patients at Risk of Venous Thromboembolism: Focus on Cross-Platform Clinical Decision Support

    System-Wide Thromboprophylaxis Interventions for Hospitalized Patients at Risk of Venous Thromboembolism: Focus on Cross-Platform Clinical Decision Support by Nikolaos Tsaftaridis, Mark Goldin, Alex C. Spyropoulos

    Published 2024-04-01
    Get full text
    Article
  4. 4
    The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes

    The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes by Alex C Spyropoulos, Sharyl Magnuson, Sei Keng Koh

    Published 2008-06-01
    Get full text
    Article
  5. 5
    The underrecognized prothrombotic vascular disease of COVID‐19

    The underrecognized prothrombotic vascular disease of COVID‐19 by Kevin P. Cohoon, Guillaume Mahé, Alex C. Spyropoulos

    Published 2020-07-01
    Get full text
    Article
  6. 6
    Emergence of institutional antithrombotic protocols for coronavirus 2019

    Emergence of institutional antithrombotic protocols for coronavirus 2019 by Kevin P. Cohoon, Guillaume Mahé, Alfonso J. Tafur, Alex C. Spyropoulos

    Published 2020-05-01
    Get full text
    Article
  7. 7
    Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis

    Management of oral anticoagulants prior to emergency surgery or with major bleeding: A survey of perioperative practices in North America: Communication from the Scientific and Sta... by Jerrold H. Levy, Jean M. Connors, Marie E. Steiner, James Douketis, Alex C. Spyropoulos

    Published 2020-05-01
    Get full text
    Article
  8. 8
    Warfarin Quality Metrics for Hospitalized Older Adults

    Warfarin Quality Metrics for Hospitalized Older Adults by Jessica Cohen, Liron Sinvani, Jason J. Wang, Andrzej Kozikowski, Vidhi Patel, Guang Qiu, Renee Pekmezaris, Alex C. Spyropoulos

    Published 2018-07-01
    Get full text
    Article
  9. 9
    Implementation of the Management of Anticoagulation in the Periprocedural Period App into an Electronic Health Record: A Cost-Effectiveness Analysis

    Implementation of the Management of Anticoagulation in the Periprocedural Period App into an Electronic Health Record: A Cost-Effectiveness Analysis by Jason J. Wang PhD, Ioannis Koulas MD, MSc, Anne Myrka BS Pharm, MAT, Alex C. Spyropoulos MD

    Published 2023-03-01
    Get full text
    Article
  10. 10
    A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant

    A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant by James D. Douketis, Summer Syed, Na Li, Samer Narouze, Mansoor Radwi, Joanne Duncan, Sam Schulman, Alex C. Spyropoulos

    Published 2021-01-01
    Get full text
    Article
  11. 11
    Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER

    Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER by Gary E. Raskob, Alex C. Spyropoulos, Theodore E. Spiro, Wentao Lu, Zhong Yuan, Bennett Levitan, Eunyoung Suh, Elliot S. Barnathan

    Published 2021-11-01
    Get full text
    Article
  12. 12
    Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records

    Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records by Alex C. Spyropoulos, James M. Crawford, Yen-Wen Cindy Chen, Veronica Ashton, Alicia K. Campbell, Dejan Milentijevic, W. Frank Peacock

    Published 2022-10-01
    Get full text
    Article
  13. 13
    Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis

    Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis by Alex C. Spyropoulos, Concetta Lipardi, Jianfeng Xu, Colleen Peluso, Theodore E. Spiro, Yoriko De Sanctis, Elliot S. Barnathan, Gary E. Raskob

    Published 2020-01-01
    Get full text
    Article
  14. 14
    Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study

    Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study by Alex C. Spyropoulos, Gary E. Raskob, Theodore E. Spiro, Wentao Lu, Yoriko De Sanctis, John Albanese, Alexandre Mebazaa, Elliot S. Barnathan

    Published 2022-10-01
    Get full text
    Article
  15. 15
    Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study

    Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study by Alfonso J. Tafur, Nathan P. Clark, Alex C. Spyropoulos, Na Li, Eric Kaplovitch, Kira MacDougall, Sam Schulman, Joseph A. Caprini, James Douketis

    Published 2020-10-01
    Get full text
    Article
  16. 16
    Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization

    Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization by Pulkit Chaudhury, Paulino Alvarez, Madonna Michael, Marwan Saad, G. Jay Bishop, Mazen Hanna, Venu Menon, Randall C. Starling, Alex C. Spyropoulos, Milind Desai, Amgad Mentias

    Published 2022-05-01
    Get full text
    Article
  17. 17
    Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials

    Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials by Dimitrios Sagris, Matilda Florentin, Panagiotis Tasoudis, Eleni Korompoki, Nikolaos Gatselis, Evangelos J. Giamarellos-Bourboulis, Haralampos Milionis, James Douketis, Alex C. Spyropoulos, George Dalekos, George Ntaios

    Published 2021-11-01
    Get full text
    Article
  18. 18
    Prognostic Value of Venous Thromboembolism Risk Assessment Models in Patients with Severe COVID-19

    Prognostic Value of Venous Thromboembolism Risk Assessment Models in Patients with Severe COVID-19 by Luis H. Paz Rios, Iva Minga, Esther Kwak, Ayman Najib, Ashley Aller, Elizabeth Lees, Victor Macrinici, Kaveh Rezaei Bookani, Amit Pursnani, Joseph Caprini, Alex C. Spyropoulos, Alfonso Tafur

    Published 2021-04-01
    Get full text
    Article
  19. 19
    The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification

    The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification by C. Michael Gibson, Alex C. Spyropoulos, Alexander T. Cohen, Russell D. Hull, Samuel Z. Goldhaber, Roger D. Yusen, Adrian F. Hernandez, Serge Korjian, Yazan Daaboul, Alex Gold, Robert A. Harrington, Gerald Chi

    Published 2017-06-01
    Get full text
    Article
  20. 20
    Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds

    Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds by Alex C. Spyropoulos MD, Bríain Ó Hartaigh PhD, Zhun Cao PhD, MA, Harjeet Caberwal PharmD, Craig Lipkin MS, Michaela Petrini PA-C, MHS, Cheng Wang MD, PhD

    Published 2022-07-01
    Get full text
    Article

Search Tools: